IP Library Granted Patent US 7,195,751
Granted Patent B2
US 7,195,751 · App. 10/765,267 · Granted Mar 27, 2007

Compositions and kits pertaining to analyte determination

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,195,751
App. No.
10/765,267
Granted
Mar 27, 2007
Kind
B2
Abstract

This invention pertains to methods, mixtures, kits and/or compositions for the determination of analytes by mass analysis using unique labeling reagents or sets of unique labeling reagents. The labeling reagents can be isomeric or isobaric and can be used to produce mixtures suitable for multiplex analysis of the labeled analytes.

Claims (94)

1. A compound of formula:

or a salt thereof, wherein,

each carbon of the heterocyclic ring has the formula C(J) 2 ;

W is NH, N—R 1 , N—R 2 , P—R 1 , P—R 2 , O, C or S;

each J is the same or different and is H, deuterium (D), R 1 , OR 1 , SR 1 , NHR 1 , N(R 1 ) 2 , fluorine, chlorine, bromine or iodine;

Z is O, S, NH or NR 1 ; and

LG is an alcohol or thiol leaving group selected from the group consisting of:

wherein,

X′ is O or S;

R 1 is the same or different and is an alkyl group comprising one to eight carbon atoms which may optionally contain a heteroatom or a substituted or unsubstituted aryl group wherein the carbon atoms of the alkyl and aryl groups independently comprise linked hydrogen, deuterium and/or fluorine atoms; and

R 2 is an amino alkyl, hydroxy alkyl, thio alkyl group or a cleavable linker that cleavably links the reagent to a solid support wherein the amino alkyl, hydroxy alkyl or thio alkyl group comprises one to eight carbon atoms, which may optionally contain a heteroatom or a substituted or unsubstituted aryl group, and wherein the carbon atoms of the alkyl and aryl groups independently comprise linked hydrogen, deuterium and/or fluorine atoms; and

wherein the compound is isotopically enriched with one or more heavy atom isotopes.

2. The compound of claim 1 , wherein the compound is isotopically enriched with three or more heavy atom isotopes.

3. The compound of claim 1 , wherein the six-membered heterocydlic ring is substituted with one or more substituents.

4. The compound of claim 3 , wherein the one or more substituents are alkyl, alkoxy or aryl groups.

5. The compound of claim 1 , wherein LG is N-hydroxysuccinimide.

6. The compound of claim 1 , wherein the compound is a salt.

7. The compound of claim 1 , wherein the compound is a mono-TFA salt, a mono-HCl salt, a bis-TFA salt or a bis-HCl salt.

8. The compound of claim 1 , wherein each incorporated heavy atom isotope is present in at least 80 percent isotopic purity.

9. The compound of claim 1 , wherein each incorporated heavy atom isotope is present in at least 93 percent isotopic purity.

10. The compound of claim 1 , wherein each incorporated heavy atom isotope is present in at least 96 percent isotopic purity.

11. A method comprising:

a) reacting an analyte with the compound of claim 1 to thereby produce a labeled analyte; and

b) mixing the labeled analyte with one or more differentially labeled analytes.

12. The compound of claim 1 of the formula:

13. The compound of claim 1 of the formula:

14. An N-substituted morpholine acetic acid active ester compound of the formula:

or a salt thereof, wherein;

LG is the Leaving group of an active ester selected from the group consisting of:

X′ is O or S;

each Z′ is independently hydrogen, deuterium, fluorine, chlorine, bromine, iodine, an amino acid side chain or a straight chain or branched C1–C6 alkyl group that may optionally contain a substituted or unsubstituted aryl group wherein the carbon atoms of the alkyl and aryl groups each independently comprise linked hydrogen, deuterium or fluorine atoms; and

wherein the N-substituted morpholine acetic add active ester is isotopically enriched with one or more heavy atom isotopes.

15. The compound of claim 14 , wherein the N-substituted morpholine acetic acid active ester is isotopically enriched with three or more heavy atom isotopes.

16. The compound of claim 14 , wherein LG is N-hydroxysuccinimide.

17. The compound of claim 14 , wherein each Z′ is independently hydrogen, deuterium, fluorine, chlorine, bromine or iodine.

18. The compound of claim 14 , wherein each Z′ is independently hydrogen or methyl.

19. The compound of claim 14 , wherein X′ is 16 O or 18 O.

20. The compound of claim 14 , wherein the nitrogen atom of the morpholine ring is 14 N or 15 N.

21. The compound of claim 14 , of the formula:

wherein;

each C* is independently 12 C or 13 C;

LG is the leaving group of an active ester as defined in claim 14 ;

X′ is O or S; and

each Z′ is independently hydrogen, deuterium, fluorine, chlorine, bromine, iodine, an amino acid side chain or a straight chain or branched C1–C6 alkyl group that may optionally contain a substituted or unsubstituted aryl group wherein the carbon atoms of the alkyl and aryl groups each independently comprise linked hydrogen, deuterium or fluorine atoms.

22. The compound of claim 14 , wherein the compound is a mono-TFA salt or a mono-HCl salt.

23. The compound of claim 14 , wherein each incorporated heavy atom isotope is present in at least 80 percent isotopic purity.

24. The compound of claim 14 , wherein each incorporated heavy atom isotope is present in at least 93 percent or isotopic purity.

25. The compound of claim 14 , wherein each incorporated heavy atom isotope is present in at least 96 percent or isotopic purity.

26. An N-substituted piperidine acetic add active ester compound of the formula:

or a salt thereof, wherein;

LG is the leaving group of an active ester selected from the group consisting of:

X′ is O or S;

each Z′ is independently hydrogen, deuterium, fluorine, chlorine, bromine, iodine, an amino add side chain or a straight chain or branched C1–C6 allyl group that may optionally contain a substituted or unsubstituted aryl group wherein the carbon atoms of the alkyl and aryl groups each independently comprise linked hydrogen, deuterium or fluorine atoms; and

wherein the N-substituted piperidine acetic acid active ester is isotopically enriched with one or more heavy atom isotopes.

27. The compound of claim 26 , wherein the N-substituted piperidine acetic acid active ester is isotopically enriched with three or more heavy atom isotopes.

28. The compound of claim 26 , wherein LG is N-hydroxysuccinimide.

29. The compound of claim 26 , wherein each Z′ is independently hydrogen, deuterium, fluorine, chlorine, bromine or iodine.

30. The compound of claim 26 , wherein each Z′ is independently hydrogen or methyl.

31. The compound of claim 26 , wherein X′ is 16 O or 16 O.

32. The compound of claim 26 , wherein the nitrogen atom of the piperidine ring is 14 N or 15 N.

33. The compound of claim 26 , of the formula:

wherein;

each C* is independently 12 C or 13 C;

LG is the leaving group of an active ester as defined in claim 26 ;

X′ is O or S; and

each Z′ is independently hydrogen, deuterium, fluorine, chlorine, bromine, iodine, an amino acid side chain or a straight chain or branched C1–C6 alkyl group that may optionally contain a substituted or unsubstituted aryl group wherein the carbon atoms of the alkyl and aryl groups each independently comprise linked hydrogen, deuterium or fluorine atoms.

34. The compound of claim 26 , wherein the compound is a mono-TFA salt or a mono-HCl salt.

35. The compound of claim 26 , wherein each incorporated heavy atom isotope is present in at least 80 percent isotopic purity.

36. The compound of claim 26 , wherein each incorporated heavy atom isotope is present in at least 93 percent or isotopic purity.

37. The compound of claim 26 , wherein each incorporated heavy atom isotope is present in at least 96 percent or isotopic purity.

38. An N-substituted piperazine acetic acid active ester compound of the formula:

or a salt thereof, wherein;

LG is the leaving group of an active ester selected from the group consisting of:

X′ is O or S;

Pg is an amine-protecting group;

each Z′ is independently hydrogen, deuterium, fluorine, chlorine, bromine, iodine, an amino acid side chain or a straight chain or branched C1–C6 alkyl group that may optionally contain a substituted or unsubstituted aryl group wherein the carbon atoms of the alkyl and aryl groups each independently comprise linked hydrogen, deuterium or fluorine atoms; and

wherein the N-substituted piperazine acetic acid active ester is isotopically enriched with one or more heavy atom isotopes.

39. The compound of claim 38 , wherein the N-substituted piperazine acetic add active ester is isotopically enriched with three or more heavy atom isotopes.

40. The compound of claim 38 , wherein LG is N-hydroxysuccinimide.

41. The compound of claim 38 , wherein each Z′ is independently hydrogen, deuterium, fluorine, chlorine, bromine or iodine.

42. The compound of claim 38 , wherein each Z′ is independently hydrogen or methyl.

43. The compound of claim 38 , wherein X′ is 16 O or 18 O.

44. The compound of claim 38 , wherein each nitrogen atom of the piperazine ring is 14 N or 15 N.

45. The compound of claim 38 , of the formula:

wherein,

each C* is independently 12 C or 13 C;

LG is the leaving group of an active ester as defined in claim 38 ;

X′ is O or S;

Pg is an amine protecting group; and

each Z′ is independently hydrogen, deuterium, fluorine, chlorine, bromine, iodine, an amino acid side chain or a straight chain or branched C1–C6 alkyl group that may optionally contain a substituted or unsubstituted aryl group wherein the carbon atoms of the alkyl and aryl groups each independently comprise linked hydrogen, deuterium or fluorine atoms.

46. The compound of claim 38 , wherein the compound is a mono-TFA salt, a mono-HCl salt, a bis-TFA salt or a bis-HCl salt.

47. The compound of claim 38 , wherein each incorporated heavy atom isotope is present in at least 80 percent isotopic purity.

48. The compound of claim 38 , wherein each incorporated heavy atom isotope is present in at least 93 percent or isotopic purity.

49. The compound of claim 38 , wherein each incorporated heavy atom isotope is present in at least 96 percent or isotopic purity.

Assignments (12)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 030182 FRAME: 0677. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Recorded Mar 4, 2016
From: BANK OF AMERICA, N.A.
To: APPLIED BIOSYSTEMS, LLC
Reel/Frame 038007/0115 →
LIEN RELEASE Recorded Apr 9, 2013
From: BANK OF AMERICA, N.A.
To: APPLIED BIOSYSTEMS, INC.
Reel/Frame 030182/0677 →
RELEASE OF SECURITY INTEREST Recorded Mar 31, 2010
From: BANK OF AMERICA, N.A.
To: APPLIED BIOSYSTEMS, LLC
Reel/Frame 024160/0955 →
CHANGE OF NAME Recorded Feb 26, 2010
From: APPLERA CORPORATION
To: APPLIED BIOSYSTEMS INC.
Reel/Frame 023994/0538 →
MERGER Recorded Feb 26, 2010
From: APPLIED BIOSYSTEMS INC.
To: APPLIED BIOSYSTEMS, LLC
Reel/Frame 023994/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2010
From: APPLIED BIOSYSTEMS, LLC
To: DH TECHNOLOGIES PTE. LTD.
Reel/Frame 023937/0854 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA FOR ASSIGNOR ATOM ACQUISITION CORPORATION TO ATOM ACQUISITION, LLC PREVIOUSLY RECORDED ON REEL 023150 FRAME 0259. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT CONVEYING PARTIES SHOULD BE LISTED AS APPLIED BIOSYSTEMS INC. AND ATOM ACQUISITION, LLC. Recorded Nov 11, 2009
From: ATOM ACQUISITION, LLC; APPLIED BIOSYSTEMS INC.
To: APPLIED BIOSYSTEMS, LLC
Reel/Frame 023500/0984 →
MERGER Recorded Aug 26, 2009
From: ATOM ACQUISITION CORPORATION; APPLIED BIOSYSTEMS INC.
To: APPLIED BIOSYSTEMS, LLC
Reel/Frame 023150/0259 →
MERGER Recorded Aug 26, 2009
From: ATOM ACQUISITION CORPORATION
To: APPLIED BIOSYSTEMS INC.
Reel/Frame 023150/0124 →
MERGER Recorded Aug 26, 2009
From: APPLERA CORPORATION
To: APPLIED BIOSYSTEMS INC.
Reel/Frame 023150/0025 →
SECURITY AGREEMENT Recorded Dec 5, 2008
From: APPLIED BIOSYSTEMS, LLC
To: BANK OF AMERICA, N.A, AS COLLATERAL AGENT
Reel/Frame 021976/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2004
From: PAPPIN, DARRYL C.; BARTLET-JONES, MICHAEL
To: APPLERA CORPORATION
Reel/Frame 014764/0405 →